Poly-ADP-ribose polymerase (PARP) inhibitors are anti-cancer drugs, and the effectiveness of first-line maintenance therapy in the treatment of ovarian cancer patients has recently been proven through several studies [4,5,6,7]. Here, PARP1 is linked to ovarian carcinoma.